Table 3 Uni- and multivariate analyses for the presence of BRAF mutation in the population of RAS-wt patients
From: Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
TS ( N =281) | VS ( N =262) | |||||||
|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | |
Gender | ||||||||
F vs M | 2.78 (1.51–5.11) | 0.001 | 2.90 (1.14–7.37) | 0.025 | 2.31 (1.23–4.33) | 0.009 | 1.92 (0.92–3.97) | 0.08 |
Age (cut-off: 65 years) | ||||||||
⩾65 vs <65 | 1.03 (1.00–1.06) | 0.030 | – | 0.11 | 1.42 (0.76–2.68) | 0.27 | – | – |
ECOG-PS | ||||||||
⩾2 vs <2 | 2.09 (1.02–4.28) | 0.044 | – | 0.87 | 1.30 (0.54–3.12) | 0.55 | – | – |
Synchronous metastases | ||||||||
yes vs no | 1.17 (0.63–2.19) | 0.606 | – | – | 1.34 (0.72–2.50) | 0.35 | – | - |
Primary site | ||||||||
right vs left | 7.12 (3.74–13.56) | 0.0001 | 7.80 (3.05–19.92) | <0.0001 | 11.14 (5.50–22.56) | <0.0001 | 8.68 (4.18–18.02) | <0.0001 |
Primary resected | ||||||||
no vs yes | 1.43 (0.68–3.02) | 0.339 | – | – | 1.29 (0.78–2.86) | 0.229 | – | - |
Mucinous histology | ||||||||
yes vs no | 4.69 (2.33–9.46) | 0.0001 | 4.95 (1.90–12.90) | <0.0001 | 4.61 (2.34–9.07) | <0.0001 | 3.23 (1.49–7.02) | 0.003 |
Number of metastatic site | ||||||||
>1 vs 1 | 1.21 (0.68–2.14) | 0.506 | – | – | 1.92 (1.03–3.60) | 0.04 | – | 0.34 |
Peritoneal metastases | ||||||||
yes vs no | 2.19 (1.15–4.19) | 0.017 | – | 0.17 | 2.53 (1.27–5.02) | 0.01 | – | 0.15 |
Lung metastases | ||||||||
yes vs no | 1.22 (0.59–2.51) | 0.586 | – | – | 1.12 (0.65–1.91) | 0.69 | – | – |
Distant lymp-node metastases | ||||||||
yes vs no | 2.02 (1.05–3.88) | 0.009 | – | 0.64 | 3.30 (1.72–6.33) | <0.0001 | – | 0.19 |
Tumour grading | ||||||||
3–4 vs 1–2 | 4.54 (2.18–9.48) | 0.0001 | – | 0.46 | 1.63 (0.85–3.13) | 0.14 | – | – |
